Human Bone Marrow-Derived Endothelial Progenitor Cells
Send inquiry
Catalog No. :
Product Level :
Brand :
CellType :
Tissue Source :
Species :
| Pack Size | Availability | Purity | Price |
|---|---|---|---|
| 5×10⁵Cells/T25 | 1-2days |
Basic information
| Notes | ||
|---|---|---|
| Storage Buffer | 0.25%胰蛋白酶 | |
| Similar Names | ||
| Clone Number | ||
| Isotype | ||
| Positive Control | ||
| Chemical Name | Human Bone Marrow-Derived Endothelial Progenitor Cells | |
| Remark | ||
| Storage Instructions | ||
| Cell Name | Human Bone Marrow-Derived Endothelial Progenitor Cells |
Biological information
| Growth Medium | 含FBS、生长添加剂、Penicillin、Streptomycin | |
|---|---|---|
| Species Reactivity | ||
| Growth | 贴壁 | |
| Antigen Exp | ||
| Applications | ||
| Conjugation | ||
| Clone | ||
| Storage Condition | ||
| Gene Exp | ||
| Doubling Time | ||
| Receptor Exp | ||
| Immunogen | ||
| Host Species | ||
| Generation Ratio | 可传2-3代；不建议多次传代 | |
| Characters | 内皮细胞样 |
Security information
| Culture Conditions | 气相：空气，95%；CO2，5% | |
|---|---|---|
| BSL | ||
| Notes | ||
| Liquid Frequency | 每2-3天换液一次 |
Related Literature
在现代医学和生物技术迅猛发展背景下,mRNA疫苗技术的兴起,不仅标志着疫苗研发进入了一个新时代,也为传染病预防和治疗提供了全新的思路和方法。mRNA疫苗,作为一种基于核酸的疫苗,与DNA疫苗相比,具有不整合至宿主基因组的显著优势,降低了基因突变风险。此外,与已被广泛使用的蛋白质疫苗相比,mRNA疫苗的无细胞生产方式不仅加快了疫苗的研发周期,还提高了生产效率和规模化生产的可能性。mRNA疫苗能编码多种抗原,适应多样化的微生物或病毒变体,同时结合编码抗原和佐剂的双重功能,有效激发免疫反应。
Publish Date:July 8, 2024
Publish Date:July 8, 2024
Related
History
Sorry, there is currently no browsing history
